Numinus Provides Bi-Weekly Update on Annual Filings
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) provided an update regarding its management cease trade order (MCTO) related to delayed annual filings for the fiscal year ended August 31, 2024. The British Columbia Securities Commission granted the MCTO on December 2, 2024, restricting the CEO and CFO from trading company securities until the Annual Filings are completed.
During this period, the company has suspended its share buy-back program and prohibited securities transactions with insiders or employees. While shareholders can continue trading, the company expects to complete and file the Annual Filings by January 28, 2025. The delay is attributed to unexpected complications, and bi-weekly status updates will be provided on SEDAR+.
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) ha fornito un aggiornamento riguardo all'ordine di cessazione del commercio dei titoli da parte della direzione (MCTO) relativo al ritardo nelle dichiarazioni annuali per l'anno fiscale chiuso il 31 agosto 2024. La Commissione dei titoli della Columbia Britannica ha concesso l'MCTO il 2 dicembre 2024, imponendo restrizioni al CEO e al CFO nel trading dei titoli della società fino a quando le dichiarazioni annuali non saranno completate.
Durante questo periodo, la società ha sospeso il programma di riacquisto delle azioni e vietato le transazioni con titoli da parte di insider o dipendenti. Anche se gli azionisti possono continuare a fare trading, la società prevede di completare e presentare le dichiarazioni annuali entro il 28 gennaio 2025. Il ritardo è attribuito a complicazioni inaspettate e verranno forniti aggiornamenti sullo stato ogni due settimane su SEDAR+.
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) proporcionó una actualización sobre su orden de cese de comercio por parte de la dirección (MCTO) relacionada con el retraso en las presentaciones anuales para el año fiscal que finaliza el 31 de agosto de 2024. La Comisión de Valores de Columbia Británica otorgó el MCTO el 2 de diciembre de 2024, restringiendo al CEO y al CFO de comerciar títulos de la empresa hasta que se completen las presentaciones anuales.
Durante este período, la empresa ha suspendido su programa de recompra de acciones y prohibido transacciones de valores con insiders o empleados. Aunque los accionistas pueden continuar negociando, la empresa espera completar y presentar las presentaciones anuales para el 28 de enero de 2025. El retraso se atribuye a complicaciones inesperadas, y se proporcionarán actualizaciones quincenales en SEDAR+.
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF)는 2024년 8월 31일로 종료되는 회계연도에 대한 연간 보고서 제출 지연과 관련하여 경영 진입 거래 중단 명령(MCTO)에 대한 업데이트를 제공하였습니다. 브리티시컬럼비아 증권 위원회는 2024년 12월 2일 MCTO를 승인했으며, CEO와 CFO의 회사 증권 거래를 연간 보고서가 완료될 때까지 제한합니다.
이 기간 동안 회사는 자사 주식 매입 프로그램을 중단하고 내부자 또는 직원과의 증권 거래를 금지하였습니다. 주주들은 거래를 계속할 수 있지만, 회사는 2025년 1월 28일까지 연간 보고서를 완료하고 제출할 것으로 예상합니다. 지연은 예상치 못한 복잡성으로 인한 것이며, SEDAR+에서 격주로 상태 업데이트가 제공될 것입니다.
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) a fourni une mise à jour concernant son ordre de cessation de négoce par la direction (MCTO) lié aux dépôts annuels retardés pour l'année fiscale se terminant le 31 août 2024. La Commission des valeurs mobilières de la Colombie-Britannique a accordé le MCTO le 2 décembre 2024, interdisant au PDG et au directeur financier de négocier des titres de l'entreprise jusqu'à ce que les dépôts annuels soient complétés.
Au cours de cette période, l'entreprise a suspendu son programme de rachat d'actions et interdit les transactions sur valeurs mobilières avec les initiés ou les employés. Bien que les actionnaires puissent continuer à négocier, l'entreprise prévoit de compléter et de soumettre les dépôts annuels d'ici le 28 janvier 2025. Le retard est attribué à des complications inattendues, et des mises à jour de statut seront fournies toutes les deux semaines sur SEDAR+.
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) hat ein Update zu seiner Management-Cease-Trade-Order (MCTO) im Zusammenhang mit verspäteten Jahresberichten für das am 31. August 2024 endende Geschäftsjahr gegeben. Die British Columbia Securities Commission hat die MCTO am 2. Dezember 2024 genehmigt, wodurch CEO und CFO bis zur Fertigstellung der Jahresberichte am Handel mit Unternehmenswertpapieren gehindert werden.
Während dieses Zeitraums hat das Unternehmen sein Aktienrückkaufprogramm ausgesetzt und den Handel mit Wertpapieren für Insider oder Mitarbeiter verboten. Während die Aktionäre weiterhin handeln können, erwartet das Unternehmen, die Jahresberichte bis zum 28. Januar 2025 abzuschließen und einzureichen. Die Verzögerung wird auf unerwartete Komplikationen zurückgeführt und es werden alle zwei Wochen Statusupdates auf SEDAR+ bereitgestellt.
- Shareholders maintain ability to trade securities during MCTO period
- Clear timeline provided for completing Annual Filings by January 28, 2025
- Management cease trade order (MCTO) imposed due to delayed annual filings
- Suspension of share buy-back program
- Restriction on securities transactions with insiders and employees
Further to the Company's news release dated December 3, 2024 (the "Announcement"), the Company's principal regulator, the British Columbia Securities Commission (the "Commission"), granted the MCTO on December 2, 2024, under National Policy 12-203 – Management Cease Trader Orders ("NP 12-203"). Pursuant to the MCTO, the Chief Executive Officers and the Chief Financial Officer of the Company may not trade in securities of the Company until such time as the Company files the Annual Filings and the Commission revokes the MCTO. During this period, the Company will cease any share buy-back activities under its normal course issuer bid, and has undertaken not to, directly or indirectly, issue or acquire securities from an insider or employee of the Company.
The MCTO does not affect the ability of shareholders to trade their securities.
The Company's Board of Directors and management are continuing to work with its accounting team to prepare the Annual Filings as soon as practicable. The delay in filing the Annual Filings is a result of unexpected delays experienced by the Company. It is the Company's reasonable expectation that the Annual Filings will be finalized by January 28, 2025.
The Company will issue a news release announcing completion of filing of the Annual Filings at such time as they are completed and filed. Until the Company files the Annual Filings, it will comply with the alternative information guidelines set out in under NP 12-203 including issuing bi-weekly default status reports by way of news releases, which will be filed on SEDAR+.
In addition, the Company confirms that since the date of the Announcement: (i) there has been no failure by the Company in fulfilling its stated intentions with respect to satisfying the provisions of the alternative information guidelines set out in NP 12-203; (ii) there has not been any other specified default by the Company under NP 12-203; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no other material information concerning the affairs of the Company that has not been generally disclosed.
About Numinus
Numinus Wellness Inc. (TSX: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms of depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society. Learn more at www.numinus.com and follow us on LinkedIn, Facebook, and Instagram.
Forward Looking Statements
Statements and other information contained in this press release about anticipated future events constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", and "intend" and statements that an event "may", "will", "should", "could" or "might" occur or other similar expressions. In particular, and without limitation, this news release contains forward-looking statements respecting the Company's reasonable expectation that the Annual Filings will be finalized by January 28, 2025 and the Company's compliance with the MCTO and NP 12-203. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements, including the results of further research into MDMA, if any, the FDA and other regulators' decisions in respect of MDMA and other psychedelic medications, restrictions that may be placed on the use of psychedelic compounds by regulatory authorities; safety and efficacy of psychedelic-assisted therapy; acceptance, uptake and commercialization of psychedelic assisted therapy, if any; dependence on obtaining regulatory approvals, and other risks that are set forth in our annual information form dated November 29, 2023, and available on SEDAR at www.sedarplus.ca. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. Numinus does not undertake any obligation to update forward-looking statements even if circumstances or management's estimates or opinions should change except as required by applicable laws. Investors should not place undue reliance on forward-looking statements.
View original content:https://www.prnewswire.com/news-releases/numinus-provides-bi-weekly-update-on-annual-filings-302340871.html
SOURCE Numinus Wellness Inc.
FAQ
When will Numinus Wellness (NUMIF) complete its delayed Annual Filings?
Can shareholders trade Numinus (NUMIF) stock during the management cease trade order?
What restrictions does the MCTO place on Numinus (NUMIF)?
Why was the MCTO issued for Numinus (NUMIF)?
